The Internet and various social media platforms have increasingly enabled drug and device manufacturers to more actively engage with HCPs and patients. In the absence of current FDA guidance on appropriate use of social media in non-promotional scientific communications, how can and should the biopharma industry proceed? Insights maybe derived from examining regulation for promotional communications. Join this plenary where FDA promotional law expert Dale Cooke will aim to untangle the conundrum of rapidly evolving social media platforms against slow moving regulations.
Learning objectives:
- Understand the current FDA regulations for social media promotional and non-promotional communications
- Be aware of how guidance for non-promotional communications may change in the future
You can access this item by buying entire course
Buy entire course: